A new approach for identifying patients with ovarian epithelial neoplasms based on high-resolution mass spectrometry

American Journal of Clinical Pathology

Volumn 134, Issue 6, 2010, Pages 903-909

  Silva, Elvio G ^a   Lopez, Patricia Regal ^b   Atkinson, Edward N ^a   Fente, Cristina A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

High performance liquid chromatography; High resolution mass spectrometry; HPLC HRMS; Ovarian epithelial tumors; Serum fingerprinting

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; DNA FINGERPRINTING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOLECULAR WEIGHT; OVARY TUMOR; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTADENOMA; FEMALE; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDE MAPPING; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 78649649699     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPG91UXBYFNRVO     Document Type: Article

References (21)

1. Benjapibal M, Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses. J Med Assoc Thai. 2007;90:1986-1991.
2. Bosse K, Rhiem K, Wappenschmidt B, et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol. 2006;103:1077-1082.
3. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6:e1000114. doi:10.1371/journal.pmed.1000114.
4. Kalluri M, Judson MA. Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci. 2007;334:441-443.
5. Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? imaging, biomarkers, or none of the above. J Clin Oncol. 2007;25:4159-4161.
6. Podgajski M, Kukura V, Duic Z, et al. Ascites, high CA-125 and chronic pelvic pain in an unusual clinical manifestation of Enterobius vermicularis ovarian and sigmoid colon granuloma. Eur J Gynaecol Oncol. 2007;28:513-515.
7. Romagnolo C, Trivella G, Bonacina M, et al. Preoperative diagnosis of 221 consecutive ovarian masses: scoring system and expert evaluation. Eur J Gynaecol Oncol. 2006;27:487-489.
8. Van Calster B, Timmerman D, Bourne T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst. 2007;99:1706-1714.
9. Jackson D, Craven RA, Hutson RC, et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res. 2007;13:7370-7379.
10. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14:1065-1072.
11. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-408.
12. Clarke CJ, Haselden JN. Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol Pathol. 2008;36:140-147.
13. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002;8:1439-1444.
14. Coen M, Lenz EM, Nicholson JK, et al. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol. 2003;16:295-303.
15. Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9:1-31.
16. Merz AL, Serkova NJ. Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer. Biomark Med. 2009;3:289-306.
17. Vallejo M, Garcia A, Tunon J, et al. Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal Bioanal Chem. 2009;394:1517-1524.
18. Lutz U, Lutz RW, Lutz WK. Metabolic profiling of glucuronides in human urine by LC-MS/MS and partial least-squares discriminant analysis for classification and prediction of gender. Anal Chem. 2006;78:4564-4571.
19. Silva EG, Tornos C, Deavers M, et al. Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation. Gynecol Oncol. 1998;71:240-246. (Pubitemid 28550807)
20. Silva EG, Tornos C, Fritsche HA Jr, et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol. 1997;10:879-883. (Pubitemid 27431961)
21. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemometrics. 2002;16:119-128.